Status:

UNKNOWN

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Lead Sponsor:

Beijing Chest Hospital

Conditions:

Tuberculosis, Multidrug-Resistant

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate efficacy and safety of an oral bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) short-course regimen (SCR) compared to an oral SCR not includin...

Eligibility Criteria

Inclusion

  • Has a positive sputum Mycobacterium tuberculosis culture from a test performed at screening
  • Has microbiological confirmation of rifampicin resistance by GeneXpert and to isoniazid (INH) via molecular drug-susceptibility testing (DST) showing katG mutation
  • Has a chest imaging result compatible with a diagnosis of pulmonary Tuberculosis (TB)
  • Agrees to use effective contraception during the 40-week study treatment phase. A female participant must be: of nonchildbearing potential; of childbearing potential and practicing effective methods of contraception during the 40-week study treatment phase
  • Is willing to undergo human immunodeficiency virus (HIV) testing

Exclusion

  • Has received prior treatment with bedaquiline
  • Has prior exposure to at least 1 second-line drug in the regimen for at least 4 weeks
  • Has any grade 3 or 4 laboratory abnormality as confirmed by a clinical expert
  • Has a known allergy or intolerance to bedaquiline or other drugs in the regimen
  • Is infected with a strain of nontuberculous mycobacteria
  • Is HIV-positive

Key Trial Info

Start Date :

May 10 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 8 2025

Estimated Enrollment :

212 Patients enrolled

Trial Details

Trial ID

NCT05306223

Start Date

May 10 2022

End Date

August 8 2025

Last Update

January 18 2023

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Beijing Chest Hospital

Beijing, China, 101149

2

The Eighth Medical Center of PLA General Hospital

Beijing, China

3

Changsha Central Hospital

Changsha, China

4

Public health clinical medical center of Chengdu

Chengdu, China

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China | DecenTrialz